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Purpose: To evaluate the evolution of a set of proposed pain biomarkers in the saliva of
subjects following Advanced Surface Ablation (ASA), in order to determine their validity as
objective pain measures.
Methods: A multicenter, prospective, and descriptive study was carried out to assess the
variations between biomarkers and perceived pain. The Inclusion criteria were healthy
subjects who underwent a bilateral, alcohol-assisted surface ablation with epithelial removal
(ASA). Pain intensity before and after surgery was assessed by Visual Analog Scale (VAS)
and the Numeric Pain Rating Scale (NPRS). Cortisol, sAA, sIgA, testosterone, and
sTNFαRII were assayed at four-time points (V0, baseline; V1, pre-surgery; V2, 1 hr post-
surgery, and V3, 72 hrs post-surgery). Comorbidities and Hospital Anxiety and Depression
(HADS) questionnaires were administrated before and at 6 hrs after the surgery. All patients
were treated with cold patches, topical steroids, topical cold antibiotics, and benzodiazepines
after ASA surgery. A descriptive analysis of biomarkers and pain intensity evolution and the
agreement between biomarkers and pain was performed.
Results: Concentration of sIgA and sTNFαRII post-surgery was significantly higher at each
visit compared to baseline (p-value: 0.053, p-value: <0.001, respectively). Relations between
VAS scale score and putative biomarker variations were not statistically significant except for
the sIgA but only at visit 0 (p-value: 0.024). The HADS questionnaire showed anxiety scores
between 0 and 7 in all patients before and at 6 hrs after surgery.
Conclusion: In this study, sIgA and sTNFαRII are the two potential biomarkers that present
correlation with the VAS and these salivary substances showed acceptable levels of reprodu-
cibility in healthy subjects.
Keywords: biomarkers, ocular pain, advanced surface ablation
Introduction
Research into human pain has undergone strong development over the last 25 years
and new biomarkers have emerged from different sources.1 The identification of pain
biomarkers is the third of the potential tools.2 Saliva is a good biomarker for clinical
applications. It is safe, easy, and non-invasive to collect and economic.3 The use of
saliva as a reliable substitute for blood could provide an avenue for biomarker
measurement in pain studies.4,5 During recent decades, saliva as a diagnostic and
prognostic fluid in pain research has received increasing attention.6 It is common to
find studies analyzing optimal saliva collection techniques for studying pain biomar-
kers, the most sensitive method for detecting and analyzing these biomarkers and,
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increasingly, more substances found in saliva, also present
in blood and related to pain, are analyzed.6,7
To date, the main potential pain biomarkers already
described in saliva are soluble tumor necrosis factor-α recep-
tor II (sTNFαRII),4 secretory immunoglobulin A (sIgA),8
cortisol, salivary alpha-amylase (sAA),9 and testosterone.10
Acute dental pain has been associated with an increase
in salivary cortisol,7 acute abdominal disease in horses has
produced an increase in sAA activity,11 da Silva et al
found a negative correlation between oral pain intensity
and sIgA levels in children,8 Choi et al reported the effects
of testosterone on pain,10,12 and Goodin et al has produced
several studies analyzing sTNFαRII response to experi-
mental modalities of acute pain.4,13,14
A previous study conducted by our group analyzed these
biomarkers, all together, in healthy subjects. The findings
suggested that salivary sIgA and sTNFαRII show remark-
able reproducibility.15 Owing to the controversy that exists
regarding these substances as biomarkers of pain, and
despite our previous findings, we decided to analyze all of
them in patients with acute eye pain following Advanced
Surface Ablation (ASA) surgery.
ASA is the term that grouped the techniques that have
been continuously improved from the earlier photorefractive
keratectomy (PRK). Today´s ASA covers numerous techni-
ques, such as laser epithelial keratomileusis (LASEK), epi-
LASIK, and epi-LASEK.16,17 ASA procedures are safe and
effective corneal refractive surgery techniques used to cor-
rect refractive errors.18 But one of their most important draw-
backs is the discomfort and the presence of pain in the acute
postoperative period.17 Postoperative acute ocular pain fol-
lowing ASA has been well characterized, with abundant
information on the duration, intensity, and peak of pain
following ASA in clinical practice.19 Therefore, the aim of
the current study was to evaluate variations in the five poten-
tial pain biomarkers mentioned, as detected in the saliva of
patients before and after ASA, to help determine their valid-
ity in measuring pain variations.
Materials and Methods
Ethics Statement
The studywas approved by the local Ethics Committee of the
Clinic University Hospital (Valladolid Spain) (PI 14–185,
January 2015) and followed the tenets of the Declaration of
Helsinki. Also, it complies with the Regulation 2016/679 of
the European Parliament and of the Council of 27 April 2016
on the protection of natural persons with regard to the
processing of personal data and on the free movement of
such data, as well as with the rest of the laws and regulations
in force and applicable as Spanish biomedical research reg-
ulatory requirements. All patients received written informed
consent before entering in the study. All subjects provided
their written informed consent before participation in the
study.
Design and Study Population
We conducted a multicenter, prospective, and descriptive
cohort study.
The population for this study (32 consecutive patients
from 2 different centers) is the same as that used in
a previous study conducted by our group.19 Also, a detailed
explanation of the exclusion and inclusion criteria has been
provided in our previous publication.19 In brief, all partici-
pants were healthy subjects affected by myopia (0.75 to 9
diopters (D)) or hyperopia (0.25 to 5D) with or without
astigmatism, who underwent bilateral ASA surgery. The
exclusion criteria were: age under 18 years old, any pain-
body in the preceding 7 days; previous ocular surgeries
within the last 12 months; autoimmune diseases; previous
treatment with painkillers (including anti–inflammatories),
psychotropics, anticonvulsants, or antidepressants. Two
experienced surgeons performed all the ASA surgeries.
Data on gender, ocular comorbidities, pain intensity,
and rescue medication administered within 72 hrs after
ASA surgery was recorded.
Hospital Anxiety and Depression (HADS) and quality
of life (QoL) questionnaires were gathered before and 6 hrs
afterward the surgery. Additionally, any post-operatively
adverse events up to 7 days following the ASA surgery
were registered.
ASA Technique
Detailed explanation of ASA procedure has been provided
in our previous publication.19
In the preoperative period, all patients took 0.5 mg
alprazolam 30 mins before surgery and one drop of 5%
lidocaine was applied at least three times before ASA
surgery (20 mins, 10 mins and just before the surgery).
In the intraoperative period, an ethyl alcohol solution
(17%) was placed on the cornea within an 8.5-mm solution
cone and left in place for 30 s. Then, a Merocel® sponge was
used to absorb any excess fluid. Subsequently, topical cold
balanced salt solution (BSS) was used to rinse the corneal
surface, and the corneal epitheliumwas removed with a blunt
spatula. This maneuver was followed by stromal ablation
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using theMEL 70 G excimer laser (Carl Zeiss Meditec, Jena,
Germany), which incorporates an eye-tracking system. The
diameter of the treated area was always at least 6 mm with
a transition to 9 mm.
After ablation, the surface was rinsed again with cold
BSS. Then, 0.3% ofloxacin and 0.18% sodium hyaluronate
drops were applied. At the end of the procedure, a therapeutic
contact lens kept at 4ºC was placed on the cornea.
In postoperative period, all patients stayed in the surgi-
cal facilities for 4 or 6 hrs following ASA. Promptly after
surgery, patients received a cold patch over the lids for 15
mins. Afterward the surgery, subjects were given to apply
cold topical antibiotics, cold topical steroids, topical 0.18%
sodium hyaluronate, and artificial tears to both eyes during
specific periods of time. Also, they were instructed to keep
all eye drops at 4ºC. Additionally, they were treated with
oral alprazolam 0.5 mg and oral vitamin C tablets.
No other painkillers were prescribed unless the pain was
deemed unbearable. In such cases, an established “rescue
medication” protocol was used. Our rescue medication pro-
tocol was described in our previous publication.16
Postoperative Pain Assessment
Pain intensity was evaluated by using the Visual Analogue
Scale (VAS) and the Numeric Pain Rating Scale (NPRS).20
Pain intensity was evaluated prior to and 0.5, 1, 2, 3, 4, 5, 6,
9, 12, 24, 36, 48 (2nd day), 60, 72 (3rd day), 96 (4th day),
120 (5th day), and 144 (6th day) hrs after ASA surgery.
Each patient was also instructed to record in an individual
diary the medication usage, pain, or depression observa-
tions at home. This methodology was described in the
previous study conducted by our group.19
Sample Collection and Analysis
The protocol on sample collection and analysis has been
previously described in previous publications.15,21 In brief,
32 subjects were instructed on how to carry out the saliva
collection using the passive secretion method21 over a 5-min
period into a collection tube. The minimum amount of sample
collected was at least 1 mL. If the 5-mL collection tube was
filled before 5 mins, the amount of elapsed time was recorded.
The samples with visible blood contamination were discarded
and after a 10-min wait, new samples were collected.
The collection of samples was obtained from each sub-
ject, in a clinical setting and was always supervised by the
investigators, in four visits: V0, baseline; V1, pre-surgery;
V2, 1 hr post-surgery, and V3, 72 hrs post-surgery.
The following salivary biomarkers were assayed by
enzyme-linked immunosorbent assay (ELISA) and ana-
lyzed using the commercially available kits: Cortisol
(DRG® Salivary Cortisol ELISA, DRG® Instruments
GmbH, Marburg, Germany), testosterone (DRG®
Salivary Testosterone ELISA, DRG Instruments GmbH,
Marburg, Germany), sAA (DRG Salivary Alpha Amylase
ELISA, DRG Instruments GmbH, Marburg, Germany),
sTNFαRII (Quantikine®, Human sTNF RII/TNFRSF1B
Immunoassay, R&D Systems, Minneapolis, MN, USA)
and sIgA (Salimetrics® Salivary Secretory IgA ELISA,
Pennsylvania, USA).
Other Ocular Symptoms, Hospital
Anxiety/Depression (HADS)
Questionnaire, Quality of Life (QoL)
Questionnaire, and Visual Function 25
(VF25) Questionnaire
The text reproduces information already reported in detail
in a study by Sobas et al.19
Other Ocular Symptoms
Basing on our previous developed questionnaire,20 we have
registered data on the presence and intensity of pain.
Accompanying ocular symptoms such as burning sensation,
photophobia, foreign body, tearing, itching, and headache
were also recorded in the questionnaire. We rated the inten-
sity of each item basing on the Likert scale of 4 points
(range 0–3, where 0 corresponded to no symptom and 3 to
the worst imaginable symptom).22
These ocular symptoms were evaluated prior to, and at
1, 6, 48, and 120 hrs after surgery. All this information was
included in the patient’s diary.
Hospital Anxiety/Depression (HADS) Questionnaire
The HADS scale, validated, and translated into Spanish
language,23 was used to assess pre- and post-surgical anxi-
ety and depression. HADS was evaluated prior to, and at 6,
48, and 120 hrs following ASA.
Full details of HADS questionnaire are given in the
following publication24 but, briefly, patients completed a self-
administered questionnaire composed of 14 items, divided
into two 7-item subscales, one for anxiety and one for depres-
sion. Both subscales had the same cut-offs: 0–7, normal;
8–10, doubtful; and ≥11, existence of a clinical problem.25
Dovepress Sobas et al
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Quality of Life (QoL) Assessment
QoL questionnaires were filled out by patients themselves.
QoL was evaluated using the QoL short form-12 (SF12)
health survey prior to, and at 24 and 72 hrs after surgery.
This self-administered questionnaire consisted of 12 ques-
tions to measure physical and mental health status;
a physical component summary (SF12 PCS) and a mental
component summary (SF12 MCS). The score was com-
puted from the scores of the twelve questions and ranged
from 0 to 100. A score of 0 indicated the lowest level of
physical and mental health, and a score of 100 indicated the
highest level.26
Visual Function 25 (VF25) Questionnaire
The VF25 questionnaire was administered prior to, and at
24 and 72 hrs after surgery. This questionnaire contains 25
questions within 11 vision subscales plus an additional
single-item general health rating question. Scoring ranges
from 0 (the lowest visual function) to 100 (best vision-
related function).26
Statistical Analysis
Sample size was based on our previously published
postoperative pain study.19 We assumed that 98% of
the participants would have ocular pain. A sample size
of 32 subjects was determined for estimating the propor-
tion of pain reporters, based on a two-sided 95% con-
fidence interval (95% CI). The margin of error was set
at ±2.5%.
Statistical analysis was performed using R software (R
Foundation for Statistical Computing, Vienna, Austria).
The significance level was set at 0.05.
Continuous variables were described as mean ± stan-
dard deviation (SD) and categorical data were summarized
as absolute frequency and percentages. Biomarker concen-
trations were analyzed as log2-transformed variables. sAA
levels were below the detection limit in two visits to
a subject. These values were imputed using the robust
regression on order statistics (ROS) method implemented
in the NADA R package.27
Linear mixed-effects models using the R package Ime4
were used to analyze the biomarkers’ evolution.28
Relationships between biomarker levels, gender,
and age were evaluated at each visit. Student’s t-test
for two independent samples and Spearman’s rank cor-
relation were used, respectively. To evaluate the rela-
tionship with the VAS scale, two groups were
considered: 0 and >0. Analysis of Variance (ANOVA)
was performed to evaluate the differences between




A total of 32 consecutive patients (19 men and 13 women)
were included between June 2015 and June 2016. The mean
age was 28.78± 6.93 and all patients received surgery on both
eyes.
Pain Evolution After ASA Procedure
All patients reported postoperative ocular pain (VAS≥20 mm)
from 0.5 to 60 hrs after surgery. The average pain intensity for
all participants increased sharply during the first 9 hrs after
surgery, and then peaked at 24 hrs (mean (SD) VAS scores of
61 (31) mm), with a 6-point difference between pre- and post-
surgical VAS at that time (p-value: 0.012). It should be high-
lighted that the value at themean (SD) time of 1 hr post-surgery
was 4.91 (1.89) mm because it was at that moment when the
biomarkers were analyzed. After that, the pain intensity was
approximately stable until 36 hrs, then it slowly decreased up
to 96 hrs after surgery. Themean (SD)VAS score at 72 hrs was
19 (20) mm.19
HADS Questionnaire
Before surgery, 29 (91%) of the patients scored between
0 and 7, [mean (SD) 4.62 (2.08)], 1 (3%) scored 10, and
1 (3%) scored ≥11 in the anxiety subscale. At 6 hrs after
surgery, all patients had anxiety scores between 0 and 7
[mean (SD) 4.38 (2.5)]. For the depression subscale, all
patients scored between 0 and 8 before surgery (1.16
± 2.07). Six hours after ASA, the results were similar
[mean (SD) 1.53 (2.09)].19
Values for All Biomarkers in the Saliva of
Healthy Subjects
The basal salivary concentrations of cortisol, sAA, sIgA,
testosterone, and sTNFαRII were previously assessed by
our group in a prospective study involving 34 pain-free
healthy subjects in two single samples at least 24 hrs
apart.15 This research showed differences in potential
biomarker concentrations between collections.
Sobas et al Dovepress
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Relationship of Biomarkers with Visits
Figure 1 shows biomarker concentration at four visits: V0,
baseline; V1, pre-surgery; V2, 1 hr post-surgery, and V3,
72 hrs post-surgery.
The levels of sIgA, sTNFαRII, and cortisol were dif-
ferent at least two visits; the effect of the visit was sig-
nificant. But sAA and testosterone remained at the limit of
significance (Table 1).
Figure 1 Biomarker concentration at four visits: V0, baseline; V1, pre-surgery; V2, 1 hr post-surgery, and V3, 72 hrs post-surgery. sIgA (μg/mL), sTNFαRII (pg/mL), cortisol
(ng/mL), AAs (U/mL), testosterone (pg/mL).
Table 1 Effect of the Visit Extracted from the ANOVA Table for the Fitted Linear Mixed Models of Each Biomarker
Sum of Squares Mean Squares gl Num gl Denom F-value p-value
IgA visit 22.255 7.4182 3 93 6.6935 0.0003856
sTNFαRII visit 11.322 3.774 3 93 9.3961 1.741e-05
Cortisol visit 7.0011 2.3337 3 93 11.554 1.663e-06
sAA visit 2.2329 0.7443 3 93 2.2448 0.08824
Testosterone visit 0.47536 0.15845 3 93 2.3945 0.0733
Note: The bold text represents sIgA, sTNFαRII, and cortisol, were different at least two visits, the effect of the visit was significant.
Abbreviations: sIgA, secretory IgA; sTNFαRII, soluble fraction of receptor II of tumor necrosis factor α; sAA, α-amylase.
Dovepress Sobas et al
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Table 2 (A) Average Levels of sIgA at All Visits; (B) Difference Between Averages of Significant Effects in sIgA Levels at All Visits
(A)
Effect Log2 µg/mL
Est. CI95% Est. Est. CI95% for Est.
Inf. Sup. Inf. Sup.
Visit V0 6.8 6.409 7.199 111.71 84.952 146.887
V1 6.33 5.94 6.73 80.72 61.389 106.145
V2 7.35 6.955 7.745 163.14 124.07 214.524
V3 6.34 5.946 6.736 81.04 61.633 106.568
(B)
Effect Visit Dif. Log2
(I)−(II)
CI95% Dif. t-value p-value
(I) (II) Inf. Sup.
Visit V0 V1 0.47 −0.22 1.157 1.7807 0.2891
V2 −0.55 −1.235 0.142 −2.0762 0.1685
V3 0.46 −0.226 1.151 1.759 0.2997
V1 V2 −1.02 −1.704 −0.327 −3.857 0.0012
V3 −0.01 −0.694 0.683 −0.0218 1
V2 V3 1.01 0.321 1.698 3.8352 0.0013
Note: The bold text represents statistically significant values.
Abbreviations: sIgA, secretory IgA µg/mL; Log2, log values of sIgA; CI, confidence interval; Est, statistic value.




Est. CI95% Est. Est. CI95% for est.
Inf. Sup. Inf. Sup.
Visit V0 6.39 5.971 6.816 84.08 62.746 112.68
V1 5.78 5.354 6.199 54.82 40.909 73.464
V2 6.48 6.059 6.904 89.35 66.672 119.73
V3 5.94 5.515 6.36 61.28 45.726 82.115
(B)
Effect Visit Dif. Log2
(I)−(II)
CI95% Dif. t-value p-value
(I) (II) Inf. Sup.
Visit V0 V1 0.62 0.203 1.032 3.8949 0.001
V2 −0.09 −0.502 0.327 −0.5526 0.9456
V3 0.46 0.042 0.871 2.8812 0.0249
V1 V2 −0.7 −1.119 −0.29 −4.4475 0.0001
V3 −0.16 −0.575 0.254 −1.0137 0.7419
V2 V3 0.54 0.13 0.959 3.4338 0.0049
Note: The bold text represents statistically significant values.
Abbreviations: sTNFαRII, soluble fraction of receptor II of tumor necrosis factor α pg/mL; Log2, log values of sTNFαRII; CI, Confidence Interval; Est, statistic value.
Sobas et al Dovepress

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
The evolution of each biomarker was assessed. Table 2
shows the sIgA levels at all visits. The highest levels are
observed at V2. The level of sIgA at V2 was significantly
higher than at V1 (p=0.001) and V3 (p=0.001). At V2, the
sIgA level was approximately 2 times the level detected at
V1 and 2 times that detected at V3 (Table 2A and B).
The level of sTNFαRII at V2 was significantly higher
than at V1 (p=<0.001) and V3 (p=0.005). The V2 level was
approximately 1.62 times the V1 level and 1.45 times the
level detected at V3 (Table 3A and B).
The highest levels of cortisol are observed at V1 and the
levels decrease to levels close to the baseline until V3. The
level of Cortisol at V0 was significantly lower than at V1 and
V2. TheV1 levelwas approximately 1.5 times theV0 level and
the V2 level 1.3 times that detected at V0 (Table 4A and B).
The differences of sAA levels were not statistically sig-
nificant at any visit. But it should be mentioned that, with
a significant level <0.1, the level of Alpha amylase at V0 was
significantly higher than at V2 (1.3 times) (Table 5A and B).
Testosterone did not show statistically significant differ-
ences at any of the visits. Also, worthy of highlight, with
a level of 0.01, the testosterone level at V1 is significantly
(approximately 1.1 times) higher than at V2 (Table 6A and B).
Table 4 (A) Average Levels of Cortisol at All Visits; (B) Difference Between Averages of Significant Effects in Levels of Cortisol at All Visits
(A)
Effect Log2 ng/mL
Est. CI95% Est. Est. CI95% for Est.
Inf. Sup. Inf. Sup.
Visit V0 2.01 1.773 2.24 4.02 3.418 4.725
V1 2.61 2.375 2.842 6.1 5.186 7.169
V2 2.38 2.145 2.612 5.2 4.424 6.115
V3 2.12 1.883 2.35 4.34 3.689 5.099
(B)
Effect Visit Dif. Log2
(I)−(II)
CI95% Dif. t-value p-value
(I) (II) Inf. Sup.
Visit V0 V1 −0.6 −0.895 −0.308 −5.3534 <0.0001
V2 −0.37 −0.666 −0.078 −3.3133 0.0071
V3 −0.11 −0.404 0.184 −0.9805 0.7609
V1 V2 0.23 −0.065 0.523 2.0401 0.1809
V3 0.49 0.197 0.785 4.3729 0.0002
V2 V3 0.26 −0.032 0.556 2.3328 0.098
Note: The bold text represents statistically significant values.
Abbreviations: cortisol, ng/mL; Log2, log values of cortisol; CI, confidence interval; Est: statistic value.
Table 5 (A) Average Levels of sAA at All Visits (Average); (B)
Difference Between Averages of Significant Effects in Levels of
sAA at All Visits
(A)
Effect Log2 U/mL
Est. CI95% Est. Est. CI95% for Est.
Inf. Sup. Inf. Sup.
Visit V0 6.22 5.909 6.523 74.32 60.068 91.959
V1 6 5.695 6.31 64.1 51.81 79.317
V2 5.88 5.571 6.185 58.81 47.531 72.766





CI95% Dif. t-value p-value
(I) (II) Inf. Sup.
Visit V0 V1 0.2 −0.181 0.572 1.3571 0.5293
V2 0.35 −0.029 0.724 2.4122 0.0818
V3 0.29 −0.085 0.668 2.0246 0.1864
V1 V2 0.15 −0.225 0.528 1.0551 0.7175
V3 0.1 −0.281 0.473 0.6675 0.9091
V2 V3 −0.06 −0.432 0.321 −0.3876 0.9801
Abbreviations: sAA, α-amylase U/mL; Log2, log values of sAA; CI, confidence
interval; Est, statistic value.
Dovepress Sobas et al

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Relationship of Biomarkers with
Demographic Variables
The relationship between cortisol level and age was statis-
tically significant (p=0.043) at Visit 0. It was a negative
relationship: as age increased, the level of cortisol was
lower (Figure 2). With a significant level <0.1, the relation-
ships of age with sAA and sIgA would also be significant
(p=0.056 and p=0.053, respectively). In the first case, the
relationship was positive, with higher levels among older
individuals, and in the second case, the relationship was
negative. It should be highlighted that the relationship
between sAA and age was statistically significant at
Visit 1 (p=0.041). At all visits, the level of testosterone
was statistically higher in men than in women (Table 7).
Relationship of Biomarkers with
Subjective Scales
VAS variationswere not statistically significant with any of the
biomarkers except for the sIgA, but only at V0 (p=0.024).
sIgA levels were higher in subjects with higher scores on the
VAS scale (Figure 3). At V2, sIgA remained at the limit of
significance. Two individuals were considered as outliers and
eliminated. Then, the model fulfilled all the necessary hypoth-
eses and the relationship with the VAS scale was significant.
Discussion
Our results confirm previous studies showing that ASA
produces severe pain in postoperative period, reaching
a moderate-high intensity (VAS value of 6) with a peak of
pain located between 24 and 36 hrs.18,29,30 Although the
VAS has been universally validated for the measurement of
pain, it has obvious limitations.31 Thus, there is a general
consensus that new objective measures of pain are required,
including salivary biomarkers.5,32
Our group had analyzed the inter-individual differences
and intersession variability in the saliva of healthy subjects
for the current selected biomarkers.15 We found significant
variance in male and female testosterone, indicating that
this hormone seems to be a poor salivary biomarker for
pain. However, due to recent findings by Choi on the
Table 6 (A) Average Levels of Testosterone at All Visits; (B)
Difference Between Averages of Significant Effects in Levels of
Testosterone at All Visits
(A)
Effect Log2 pg/mL
Est. CI95% Est. Est. CI95% for Est.
Inf. Sup. Inf. Sup.
Visit V0 6.01 5.794 6.228 64.49 55.497 74.942
V1 6.16 5.94 6.373 71.32 61.376 82.882
V2 6.01 5.788 6.222 64.23 55.268 74.634





CI95% Dif. t-value p-value
(I) (II) Inf. Sup.
Visit V0 V1 −0.15 −0.314 0.023 −2.2589 0.1153
V2 0.01 −0.162 0.174 0.0926 0.9997
V3 −0.03 −0.199 0.138 −0.4775 0.9639
V1 V2 0.15 −0.017 0.319 2.3515 0.094
V3 0.11 −0.054 0.283 1.7814 0.2888
V2 V3 −0.04 −0.205 0.132 −0.57 0.9407
Note: The italicized text represents statistically significant values with a level
of 0.01.
Abbreviations: Testosterone, pg/mL; Log2, log values of sAA; CI, confidence
interval; Est, statistic value.
Figure 2 Spearman correlation plot and 95% CI showing a negative correlation between cortisol level and age.
Sobas et al Dovepress

































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
importance of considering the effects of testosterone on
pain, we considered it necessary to include testosterone in
this study. Choi reported that lower levels of testosterone
allow greater tolerance to pain, an important aspect to
consider when treating patients for pain.12
The results showed that sIgA is the biomarker that
presents the highest correlation with pain. sIgA is one of
the main antibodies in the oral mucosa33 and it plays an
essential role in maintaining the integrity of the mucous
membrane.34 Its levels on the surface of oral mucosa have
been shown to be related with the regulation of the devel-
opment of inflammatory responses.34
Our results are consistent with previous reports, where
patients affected by oral lichen planus, a chronic disease,
presented higher values for sIgA than control subjects.35
However, da Silva and colleagues found a negative corre-
lation between oral pain intensity and sIgA levels in
children.8
sTNFαRII is the other biomarker whose concentration
is raised at V2. Goodin et al showed that sTNFαRII in oral
fluids significantly decreased from baseline in relation to
all three experimental pain modalities.4 Contrary to that
study, our results reported a significant increase, which
correlates with the highest values on the VAS.
Although there is a study that considered that sAA mea-
surements could be a good biomarker of pain,11 our results
did not find statistically significant differences between vis-
its. These results are consistent with a previous study carried
out by our group analyzing the reliability of this potential
pain biomarker in the saliva of healthy subjects. That study
did not find acceptable levels of reproducibility between two
measurements.15
Cortisol response to pain does not appear to be purely
a function of the pain experience, because cortisol at V0
was significantly lower than at V1 and V2. It may be that
other stress-related features, such as sympathetic activa-
tion, may be involved in the cortisol elevation detected.4,36
Conclusion
In contrast to other studies, in this study, all the biomarkers
were analyzed together, relating them to the VAS and in
the postoperative period of a surgery in which the evolu-
tion of pain is well described. This is the first study using
this “clinical model” of acute postoperative pain, which in
our opinion has some advantages. Patients who are going
to undergo ASA surgery are healthy patients, without pain
prior to surgery.
Regarding the increase of cortisol concentration at the
pre-surgery visit, we believe that it is related to the presence
of anxiety and depression as detected by the HADS scale. It
Table 7 Testosterone Levels in Males and in Females at All Visits
Visit Gender Mean SD P-value
V0 M 82.33 30.96 0.0034
F 53.84 22.75
V1 M 88.73 28.46 0.0005
F 57.86 18.05
V2 M 83.46 34.14 0.0017
F 51.87 19.62
V3 M 86.87 28.51 0.0001
F 49.79 17.76
Notes: N= 19 males, 13 females. V0, baseline; V1, pre-surgery; V2, 1 hr post-
surgery, and V3, 72 hrs post-surgery.
Abbreviation: SD, standard deviation.
Figure 3 The graph presents the relationship between VAS and sIgA at V0. VAS is considered as a discrete variable with two levels: 0 and >0 (up to a maximum of 2). IgA
levels are significantly higher in the group of individuals that score higher than 0 on the VAS scale. The VAS is statistically significant at IgA levels.
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can be concluded that cortisol, under these circumstances,
could be a biomarker more related to stress than to pain.
In this study, sIgA and sTNFαRII are the two potential
biomarkers that present correlation with the VAS and these
salivary substances showed acceptable levels of reprodu-
cibility in healthy subjects.15 Nevertheless, further studies
are required, including studies with other types of post-
surgical pain before proposing them as valid pain biomar-
kers in future clinical studies.
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